Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study. (PubMed, Medicina (Kaunas)) - Sep 27, 2026 - "GLP-1-based medication status was defined by a hospital medication-field entry for exenatide, dulaglutide, semaglutide, a fixed-ratio insulin/GLP-1 receptor agonist combination, or tirzepatide, a dual GIP/GLP-1 receptor agonist...Heart failure was documented in 35.7% versus 22.2%, and any lower-limb amputation in 3.3% versus 1.2%... A GLP-1-based medication record identified a clinically complex subgroup with documented DPN. The findings are exploratory and hypothesis-generating; because treatment and outcome dates were unavailable, they do not establish temporality, treatment benefit, or treatment harm."
Journal • Observational data • Retrospective data • Cardiovascular • Congestive Heart Failure • Diabetes • Diabetic Neuropathy • Heart Failure • Metabolic Disorders • Pain
|
|
Anca Cristina Ferician; Mihaela Simona Popoviciu; Timea Claudia Ghitea
|